185 related articles for article (PubMed ID: 36374143)
21. Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.
Gracia-Cazaña T; Mascaraque M; Lucena SR; Vera-Álvarez J; González S; Juarranz Á; Gilaberte Y
PLoS One; 2019; 14(4):e0215537. PubMed ID: 31017970
[TBL] [Abstract][Full Text] [Related]
22. Basosquamous cell carcinoma: a survey of 76 patients and a comparative analysis of basal cell carcinomas and squamous cell carcinomas.
Betti R; Crosti C; Ghiozzi S; Cerri A; Moneghini L; Menni S
Eur J Dermatol; 2013; 23(1):83-6. PubMed ID: 23238332
[TBL] [Abstract][Full Text] [Related]
23. Myofibroblast stroma differentiation in infiltrative basal cell carcinoma is accompanied by regulatory T-cells.
Ressler JM; Zila N; Korosec A; Yu J; Silmbrod R; Bachmayr V; Tittes J; Strobl J; Lichtenberger BM; Hoeller C; Petzelbauer P
J Cutan Pathol; 2023 Jun; 50(6):544-551. PubMed ID: 36562598
[TBL] [Abstract][Full Text] [Related]
24. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.
Bolshakov S; Walker CM; Strom SS; Selvan MS; Clayman GL; El-Naggar A; Lippman SM; Kripke ML; Ananthaswamy HN
Clin Cancer Res; 2003 Jan; 9(1):228-34. PubMed ID: 12538474
[TBL] [Abstract][Full Text] [Related]
25. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma.
Adegboyega PA; Rodriguez S; McLarty J
Hum Pathol; 2010 Aug; 41(8):1128-37. PubMed ID: 20381122
[TBL] [Abstract][Full Text] [Related]
26. Basaloid/follicular hyperplasia overlying connective tissue/mesenchymal hamartomas simulating basal cell carcinomas.
Stashower ME; Smith K; Corbett D; Skelton HG
J Am Acad Dermatol; 2001 Dec; 45(6):886-91. PubMed ID: 11712034
[TBL] [Abstract][Full Text] [Related]
27. Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma.
Tilli CM; Ramaekers FC; Broers JL; Hutchison CJ; Neumann HA
Br J Dermatol; 2003 Jan; 148(1):102-9. PubMed ID: 12534602
[TBL] [Abstract][Full Text] [Related]
28. Expression of p53 in arsenic-related and sporadic basal cell carcinoma.
Boonchai W; Walsh M; Cummings M; Chenevix-Trench G
Arch Dermatol; 2000 Feb; 136(2):195-8. PubMed ID: 10677095
[TBL] [Abstract][Full Text] [Related]
29. Expression of CXCR4, MMP-13 and β-catenin in different histological subtypes of facial basal cell carcinoma.
Ciurea ME; Cernea D; Georgescu CC; Cotoi OS; Pătraşcu V; Pârvănescu H; Popa D; Pârvănescu V; Ciurea RN; Mercuţ R
Rom J Morphol Embryol; 2013; 54(4):939-51. PubMed ID: 24398989
[TBL] [Abstract][Full Text] [Related]
30. Desmoplastic Trichoepithelioma: An Uncommon but Diagnostically Problematic Benign Adnexal Tumor.
Bartoš V
Acta Dermatovenerol Croat; 2019 Dec; 27(4):282-284. PubMed ID: 31969246
[TBL] [Abstract][Full Text] [Related]
31. Expression of β-Catenin, E-Cadherin, and α-Smooth Muscle Actin in Basal Cell Carcinoma Before Photodynamic Therapy in Non-recurrent and Recurrent Tumors: Exploring the Ability of Predicting Photodynamic Therapy Outcome.
Mørk E; Mjønes P; Foss OA; Bachmann IM; Christensen E
J Histochem Cytochem; 2023 Mar; 71(3):111-120. PubMed ID: 36961748
[TBL] [Abstract][Full Text] [Related]
32. Presence of ulceration, but not high risk zone location, correlates with unfavorable histopathological subtype in facial basal cell carcinoma.
Yalcin O; Sezer E; Kabukcuoglu F; Kilic AI; Sari AG; Cerman AA; Altunay IK
Int J Clin Exp Pathol; 2015; 8(11):15448-53. PubMed ID: 26823913
[TBL] [Abstract][Full Text] [Related]
33. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
Pilloni L; Bianco P; Manieli C; Senes G; Coni P; Atzori L; Aste N; Faa G
Eur J Histochem; 2009 Jun; 53(2):e14. PubMed ID: 30256877
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of CXCR4, α-SMA and WASL in upper lip basal cell carcinomas.
Sălan AI; Mărăşescu PC; Camen A; Ciucă EM; Matei M; Florescu AM; Pădureanu V; Mărgăritescu C
Rom J Morphol Embryol; 2018; 59(3):839-849. PubMed ID: 30534824
[TBL] [Abstract][Full Text] [Related]
35. Basal cell carcinoma of the skin with mixed histomorphology: a comparative study.
Bartoš V; Kullová M
Cesk Patol; 2016; 52(4):222-226. PubMed ID: 27869450
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical Expression of Calponin in Cutaneous Basal Cell Carcinoma.
Bartoš V; Kullová M
Acta Dermatovenerol Croat; 2015; 23(4):254-9. PubMed ID: 26724876
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of COX-2 in recurrent basal cell carcinoma of the skin: a pilot study.
Karahan N; Baspinar S; Bozkurt KK; Caloglu E; Ciris IM; Kapucuoglu N
Indian J Pathol Microbiol; 2011; 54(3):526-31. PubMed ID: 21934214
[TBL] [Abstract][Full Text] [Related]
38. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical prognostic criteria in xeroderma pigmentosum.
Karakok M; Turkmen A; Bekerecioglu M; Koçer NE
Int J Dermatol; 2010 Nov; 49(11):1266-71. PubMed ID: 21038547
[TBL] [Abstract][Full Text] [Related]
40. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma.
Law AM; Oliveri CV; Pacheco-Quinto X; Horenstein MG
J Cutan Pathol; 2003 Apr; 30(4):232-6. PubMed ID: 12680952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
